|
292 Companies |
|
371 Products |
|
371 Products |
|
177 Mechanisms of Action |
|
18 Trials |
|
3684 News |
|
| «12...66676869707172737475767778 |
- lorvotuzumab mertansine (IMGN901) / ImmunoGen
Enrollment closed: BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Sep 11, 2011
P1, N=44, Active, not recruiting, Sponsor: ImmunoGen, Inc.
Recruiting --> Active, not recruiting
- sunitinib / Generic mfg.
Enrollment closed, Surgery: Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma (clinicaltrials.gov) - Sep 1, 2011
P=N/A, N=12, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- atiprimod (SK&F106615) / Synergy Pharma
Trial completion: Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma (clinicaltrials.gov) - Aug 29, 2011
P2, N=10, Completed, Sponsor: Callisto Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change, Metastases: Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Aug 24, 2011
P1, N=12, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=10 --> 12
- temozolomide / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Combination therapy: Sorafenib in Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Aug 23, 2011
P1, N=18, Active, not recruiting, Sponsor: University Hospital, Geneva
N=10 --> 12 Recruiting --> Active, not recruiting
- | Ad-RTS-hIL-12 / Alaunos Therap
Enrollment open, Combination therapy: Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma (clinicaltrials.gov) - Aug 22, 2011
P1/2, N=30, Recruiting, Sponsor: Ziopharm
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion: Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases (clinicaltrials.gov) - Aug 17, 2011
P2, N=51, Completed, Sponsor: University Hospital Tuebingen
Active, not recruiting --> Recruiting Recruiting --> Completed
- everolimus / Generic mfg.
New P2 trial: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 (clinicaltrials.gov) - Aug 16, 2011
P2, N=25, Active, not recruiting, Sponsor: New York University School of Medicine
- | Votrient (pazopanib) / Novartis, BeiGene
New P1/2 trial, Combination therapy: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Aug 14, 2011
P1/2, N=61, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Enrollment change, Metastases: Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma (clinicaltrials.gov) - Aug 11, 2011
P2, N=4, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=95 --> 4
- | Avastin (bevacizumab) / Roche
New P2 trial: ARTE: Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma (clinicaltrials.gov) - Aug 11, 2011
P2, N=60, Recruiting, Sponsor: University of Zurich
- New P2 trial, Metastases: Study of Immune Responses in Patients With Metastatic Melanoma (clinicaltrials.gov) - Aug 11, 2011
P2, N=0, Withdrawn, Sponsor: Providence Health & Services
- Trial completion, Metastases: Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma (clinicaltrials.gov) - Aug 11, 2011
P2, N=4, Completed, Sponsor: National Cancer Institute (NCI)
N=95 --> 4 Recruiting --> Completed
- Avastin (bevacizumab) / Roche, tandutinib (MLN518) / Takeda
Enrollment change, Combination therapy: Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors (clinicaltrials.gov) - Aug 8, 2011
P2, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=80 --> 42
- Avastin (bevacizumab) / Roche
New P2 trial: Bevacizumab With or Without Surgery for Adult Glioblastomas (clinicaltrials.gov) - Aug 8, 2011
P2, N=0, Withdrawn, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
- Avastin (bevacizumab) / Roche, tandutinib (MLN518) / Takeda
Trial completion, Combination therapy: Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors (clinicaltrials.gov) - Aug 8, 2011
P2, N=42, Completed, Sponsor: National Cancer Institute (NCI)
N=80 --> 42 Recruiting --> Completed
- temozolomide / Generic mfg.
Enrollment change: Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma (clinicaltrials.gov) - Aug 7, 2011
P2, N=1, Completed, Sponsor: Herbert Newton
Recruiting --> Completed N=60 --> 1
- Azedra (iobenguane I 131) / Lantheus
New P2 trial: A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors (clinicaltrials.gov) - Aug 7, 2011
P2, N=50, Completed, Sponsor: University of California, San Francisco
- temozolomide / Generic mfg.
Trial completion: Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma (clinicaltrials.gov) - Aug 7, 2011
P2, N=1, Completed, Sponsor: Herbert Newton
N=60 --> 1 No longer recruiting --> Completed